2025-04-24 04:53:58 pm | Source: PR Agency
Morepen Labs launches 4 new products -“Ticapen, UdoFix, LycoMore, Acifix”
Morepen Laboratories is pleased to announce the launch of four new products—Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing its commitment to offer innovative latest products marking an another milestone reinforcing the doctor and patient trust. These new launches reflect our unwavering focus on research-led innovation, clinical excellence, and affordable healthcare access, addressing critical needs in cardiology, hepatology, nutrition, and diabetology.
This strategic expansion reinforces Morepen’s commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control.
As India’s #1 exporter of APIs for six globally used molecules—Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine—Morepen has a presence in 82 countries, backed by an annual API manufacturing capacity of 144 metric tons. Its integrated capabilities across the pharmaceutical value chain give it a unique competitive edge in both regulated and emerging markets like the US, Europe, Japan, China, and Russia. With a current formulation business size of approximately Rs.325 crore, the company is now accelerating toward a Rs.1,000 crore target over the next five years—driven by deeper market penetration, an expanded field force, and a growing portfolio of cost-efficient, globally compliant therapies.
Above views are of the author and not of the website kindly read disclaimer
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Fourth Kautilya Economic Conclave concludes successf...
RPF, NDRF and IRIDM join hands on saving lives durin...
Quote on Market Wrap 07th October 2025 by Shrikant C...
Sensex rises 136 points, Nifty ends above 25,100 as ...
Mann Fleet Partners files for IPO with SEBI
Invesco Asset Management (India) announces Change in...
ICICI Pru MF declares IDCW under Medium Term Bond Fund
Aditya Birla SLAMC announces change in minimum appli...
Bondada Engineering surges as its arm bags orders wo...
Isgec Heavy Engineering rises on inking pact to acqu...
